OTTINI, ARIANNA
OTTINI, ARIANNA
Universita' degli Studi di MILANO
Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers
2025 F. Caspani, S. Cavalieri, E. Orlandi, C. Bergamini, C. Resteghini, E. Colombo, A. Ottini, I. Nuzzolese, S. Alfieri, A. Mirabile, A. Cassano, P. Bossi, T. Ibrahim, M.C. Cau, M. Ghiani, F. Bertolini, R. Ingargiola, G. Fontana, L. Licitra, L.D. Locati
Indirect comparison ofTPF and GP induction chemotherapy regimens in nasopharyngeal carcinoma: a data-driven reassessment before the transition to induction chemoimmunotherapy
2025 S. Cavalieri, A. Ottini, B.L. Stocchetti, L. Licitra
Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study
2025 S. Rota, S. Buriolla, A. Franza, S. Cavalieri, C. Bergamini, S. Alfieri, I. Nuzzolese, E. Colombo, A. Ottini, B. Lombardi Stocchetti, G. Massa, A. Caraceni, L. Licitra, C. Resteghini
Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study
2025 S. Alfieri, R. Romano, S. Marceglia, C. Sciortino, W. Ferrari Bravo, M. Zucchini, M.L. Piscitelli, I. Nuzzolese, S. Cavalieri, C. Bergamini, E. Colombo, A. Ottini, L. De Cecco, D. Lenoci, N.A. Iacovelli, M. Guzzo, E. Orlandi, L.D. Locati, P. Bossi, L. Licitra, F. Taverna
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study
2025 E. Colombo, S. Cavalieri, A. Vingiani, L. Agnelli, M. Duca, B. Paolini, F. Perrone, E. Tamborini, I. Capone, A. Piccolo, F. Caspani, C. Bergamini, S. Alfieri, C. Resteghini, I. Nuzzolese, A. Ottini, S. Buriolla, M. Salvetti, G. Calareso, M. Milione, G. Pruneri, L.D. Locati, L. Licitra
Lenvatinib in advanced thyroid, salivary gland, endometrial, and hepatocellular carcinomas: a real-world study on treatment duration and toxicity management
2025 E. Colombo, M. Ducceschi, S. Cavalieri, M. Polignano, M. Bini, P. Ambrosini, M. De Monte, G. Montelatici, A. Russo, V. Bellia, S. Bhoori, C. Bergamini, S. Alfieri, I. Nuzzolese, A. Ottini, V. Mazzaferro, F. Raspagliesi, L. Licitra, M. Mantiero
Claudin-1 in Head and Neck Squamous Cell Carcinoma
2024 S. Cavalieri, C. Bergamini, D. Lenoci, A. Ottini, M. Lucchetta, E. Torchia, L. Licitra, L. De Cecco
Management of patients with skin adnexal carcinomas
2023 S. Cavalieri, C. Bergamini, S. Alfieri, C. Resteghini, I. Nuzzolese, E. Colombo, A. Ottini, L. Licitra
HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
2023 S. Cavalieri, I. Nuzzolese, A. Ottini, C. Bergamini, C. Resteghini, E. Colombo, S. Alfieri, P. Quattrone, G. Calareso, N.A. Iacovelli, M. Franceschini, L. Licitra
Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature
2023 L. Giannini, A. Alliata, V. Cristofaro, F. Incandela, M. Pompilio, A. Ottini, S. Cavalieri, I. Nuzzolese, N.A. Iacovelli, M. Franceschini, A. Deganello
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience
2023 S. Cavalieri, F. Platini, F. Barretta, I. Nuzzolese, A. Ottini, C. Bergamini, C. Resteghini, E. Colombo, N.A. Iacovelli, M. Franceschini, G. Calareso, P. Di Pede, G. De Feo, M. Gandelli, L. Toffolatti, M. Guglielmo, C.I. Ripamonti, L. Cosmai, L. Licitra, S. Alfieri
Oligometastatic disease from differentiated thyroid cancer: Best treatment schemes
2023 E. Colombo, A. Ottini, L. Licitra
NUT carcinoma of the submandibular gland: A case report
2023 S. Rota, P. Quattrone, G. Centonze, G. Dagrada, A. Ottini, E. Colombo, I. Nuzzolese, G. Calareso, M. Franceschini, N.A. Iacovelli, F. Perrone, E. Tamborini, S. Cavalieri
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
2023 E. Colombo, C. Gurizzan, A. Ottini, F. Caspani, C. Bergamini, L.D. Locati, C. Marchiselli, A. Alberti, L. Lorini, L.F. Licitra, P. Bossi, C. Resteghini
Biomarker-driven immunotherapy for precision medicine in prostate cancer
2022 A. Ottini, P. Sepe, T. Beninato, M. Claps, V. Guadalupi, E. Verzoni, P. Giannatempo, G. Baciarello, F. De Braud, G. Procopio
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
2022 A. Mennitto, E. Zattarin, M. Di Maio, D. Bimbatti, U. De Giorgi, S. Buti, D. Santini, C. Casadei, M. Soraru, C. Messina, C. Mucciarini, G. Di Lorenzo, G. Roviello, C. Buttigliero, M. Stellato, P. Sepe, M. Claps, V. Guadalupi, A. Ottini, S. Pignata, F.G. De Braud, E. Verzoni, G. Procopio
Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
2021 S. Cavalieri, D.M. Filippini, A. Ottini, C. Bergamini, C. Resteghini, E. Colombo, R. Lombardo, I. Nuzzolese, S. Alfieri, L. Licitra, L.D. Locati
Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic
2021 S. Cavalieri, E. Colombo, A. Bottiglieri, G. Massa, F. Platini, A. Ottini, D. Filippini, E. Zattarin, C. Bergamini, C. Resteghini, S. Alfieri, V. Di Martino, V. Tiraferri, L. Locati, L. Licitra
Management of serious complications in intra-abdominal desmoid-type fibromatosis
2021 F. Bini, M. Fiore, S. Provenzano, R. Bertulli, A. Ottini, C. Colombo, M. Vitellaro, G. Greco, C. Morosi, A. Gronchi, P.G. Casali, E. Palassini
Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients
2021 F. Ligorio, L. Zambelli, A. Bottiglieri, L. Castagnoli, E. Zattarin, R. Lobefaro, A. Ottini, A. Vingiani, S.M. Pupa, G.V. Bianchi, G. Capri, G. Pruneri, F. de Braud, C. Vernieri